Board of Directors

Roger I. Gale, M.E., Executive Chairman

Mr. Gale is Executive Chairman of Sedia Biosciences.  He also serves as Company Treasurer and Company Secretary. Mr. Gale served as Sedia’s Chief Executive Officer from the Company’s inception in 2009 until January 2021. He is a co-founder of the Company. Mr. Gale also served as an Independent Director of Mechel OAO, (NYSE: MTL) from 2004 to June 2014.  Previously, Mr. Gale served as Chairman of the Board of Calypte Biomedical Sciences from November 2004 until December 2008 and CEO and President until May 2008.  He has also served as Executive Chairman of Wavecrest Group Enterprises Limited, a United Kingdom-based communications service provider (2001-2006) and Chairman and co-founder of End2End Wireless Limited, a UK wireless access services provider (1999-2001).  He was also CEO of the Moscow–based, OPIC-guaranteed, AIG-Brunswick Millennium Fund (1995-1999) and held senior positions with the Asian Development Bank (ADB, Manila) and the International Finance Corporation (IFC, World Bank, Washington, D.C.)  Mr. Gale lectured in economics at the University of New England (Australia) and Lincoln College (New Zealand).  Mr. Gale is a graduate of the Royal Agricultural College, UK and has a Master of Economics, University of New England, Australia. 

Ronald W. Mink, Ph.D., Member of the Board

Dr. Mink became CEO in January 2021 and continues his role as President held since 2009.  He is a co-founder of the Company.  Previously, he also served as Chief Science Officer of Sedia Biosciences.  Dr. Mink has been on the board since the Company’s founding. Prior to Sedia, Dr. Mink served as Chief Science Officer (CSO) of Calypte Biosciences from June 2005 until December 2008, Director of R&D at Calypte from 2003 until 2005 and consultant to Calypte from 2001 to 2003.  At Calypte, he introduced rapid point of care diagnostic testing technology to the company, oversaw development and launch of the BED HIV-1 Incidence EIA, expanded the company’s Aware™ line of HIV products and launched the creation of its new Life Sciences Division.  Prior to Calypte, he was Director of R&D at OraSure Technologies, Inc. (NASDAQ: OSUR).  Dr. Mink holds several patents for oral fluid diagnostic tests, including the OraQuick® HIV rapid test, the first U.S. FDA approved rapid oral fluid HIV test. and other tests for oral disease pathogens.  He has prior experience successfully developing and commercializing rapid assays in such companies as Eli Lilly and Co.’s diagnostic group and Carter Wallace, culminating in the commercialization of several point-of-care and OTC diagnostic tests.  Dr. Mink received his Ph.D. in Microbiology from the University of Illinois and B.S. and M.S. from Ohio State University.

Lynnor Stevenson, Ph.D., Member of the Board

Dr. Stevenson has served as a board member of Sedia since 2010. She was formerly Chair and Chief Executive Officer of DesignMedix, a pharmaceutical company focused on globally-important infectious diseases including malaria.  Dr. Stevenson is a successful entrepreneur with forty years experience in the formation and growth of bioscience companies.  She was a Managing Partner of Alta Biomedical Group, a consulting firm with projects in the commercialization of innovative technology. She has been a member of the early-stage management teams for ten start-up companies, six of which are now public. She was founding CEO for 5 years and a director for 18 years of Heska Corporation, an animal health company that develops drugs, vaccines and diagnostics. She was a member of the early-stage teams for Creative BioMolecules (now Curis), AP Pharma, Agen and Univax (now Nabi) and is a founder and director of CytoImage Inc, a company developing single cell cancer diagnosis. In addition to business and R&D experience relating to drugs, vaccines and diagnostics, she has experience in drug development at several companies including the submission of several IND (Investigational New Drug) applications to the FDA. She received B.Sc.Hon. and B.Ed. degrees from Melbourne University and a Ph.D in Biochemistry from Monash University, Australia. 

For information about Sedia's Management Team, click here.

| Home | About Us | Contact Us | Jobs | Privacy Policy | Terms and Conditions | Search | Site Map |     © Copyright 2018 - Sedia Biosciences Corporation
Top